Astera Cancer Care is proud to announce that we have enrolled our first patient in a groundbreaking first-in-human (FIH) clinical trial, becoming the first community site in the United States to do so. This milestone signifies our commitment to bringing cutting-edge cancer treatment options to our community. Our participation follows Washington University School of Medicine, which enrolled the first U.S. patient in this trial approximately three weeks ago.
The trial, titled "A Phase 1a/1b Study of BG-68501, a Selective CDK2 Inhibitor, in Participants with Advanced Solid Tumors," aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BG-68501. This innovative investigational therapy from BeiGene, administered as an oral tablet, is designed for patients with advanced, nonresectable, or metastatic solid tumors. The study is structured in two parts: dose escalation and safety expansion (Part 1), followed by dose expansion (Part 2).
Astera Cancer Care's involvement as the first community clinic in the U.S. to enroll a patient highlights our dedication to advancing cancer research and providing our patients with access to the latest therapeutic advancements. We are optimistic that BG-68501 will offer new hope for those battling advanced-stage cancers, and we are honored to contribute to this study.
published: Oct. 18, 2024, 1:14 p.m.